Your browser doesn't support javascript.
loading
Cytochrome P450-Mediated Metabolism and CYP Inhibition for the Synthetic Peroxide Antimalarial OZ439.
Shackleford, David M; Chiu, Francis C K; Katneni, Kasiram; Blundell, Scott; McLaren, Jenna; Wang, Xiaofang; Zhou, Lin; Sriraghavan, Kamaraj; Alker, André M; Hunziker, Daniel; Scheurer, Christian; Zhao, Qingjie; Dong, Yuxiang; Möhrle, Jörg J; Abla, Nada; Matile, Hugues; Wittlin, Sergio; Vennerstrom, Jonathan L; Charman, Susan A.
Afiliação
  • Shackleford DM; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia.
  • Chiu FCK; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia.
  • Katneni K; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia.
  • Blundell S; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia.
  • McLaren J; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia.
  • Wang X; College of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
  • Zhou L; College of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
  • Sriraghavan K; College of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
  • Alker AM; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
  • Hunziker D; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
  • Scheurer C; Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4002 Basel, Switzerland.
  • Zhao Q; University of Basel, CH-4003 Basel, Switzerland.
  • Dong Y; College of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
  • Möhrle JJ; College of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
  • Abla N; Medicines for Malaria Venture, 20 Route de Pré-Bois, CH-1215 Geneva 15, Switzerland.
  • Matile H; Medicines for Malaria Venture, 20 Route de Pré-Bois, CH-1215 Geneva 15, Switzerland.
  • Wittlin S; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
  • Vennerstrom JL; Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4002 Basel, Switzerland.
  • Charman SA; University of Basel, CH-4003 Basel, Switzerland.
ACS Infect Dis ; 7(7): 1885-1893, 2021 07 09.
Article em En | MEDLINE | ID: mdl-34101429
ABSTRACT
OZ439 is a potent synthetic ozonide evaluated for the treatment of uncomplicated malaria. The metabolite profile of OZ439 was characterized in vitro using human liver microsomes combined with LC/MS-MS, chemical derivatization, and metabolite synthesis. The primary biotransformations were monohydroxylation at the three distal carbon atoms of the spiroadamantane substructure, with minor contributions from N-oxidation of the morpholine nitrogen and deethylation cleavage of the morpholine ring. Secondary transformations resulted in the formation of dihydroxylation metabolites and metabolites containing both monohydroxylation and morpholine N-oxidation. With the exception of two minor metabolites, none of the other metabolites had appreciable antimalarial activity. Reaction phenotyping indicated that CYP3A4 is the enzyme responsible for the metabolism of OZ439, and it was found to inhibit CYP3A via both direct and mechanism-based inhibition. Elucidation of the metabolic pathways and kinetics will assist with efforts to predict potential metabolic drug-drug interactions and support physiologically based pharmacokinetic (PBPK) modeling.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antimaláricos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antimaláricos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article